PURPOSE: A dose-searching study was carried out treating selected elderly patients or patients with poor performance with bladder cancer with once weekly fractionation to determine an effective dose per fraction, and to evaluate acute and late effects resulting from this schedule. METHODS AND MATERIALS: Seventy patients with invasive transitional cell carcinoma of the bladder were entered in the study. The dose used was 36-39 Gy in six fractions over 35 days in 27 patients (Group 1). The remaining 43 patients were treated with 34.5 Gy in six fractions over 39 days (Group 2). RESULTS: Six patients developed Grade 1-2 European Organization for Research on Treatment of Cancer (EORTC) bowel reaction. Three patients in Group 1 developed Grade 3 late bowel reaction and a fourth patient developed Grade 4 reaction requiring colostomy. However, only one patient in Group 2 developed Grade 3 reaction. The difference between the two groups was statistically significant (chi 2 = 3.794, p = 0.05). CONCLUSIONS: The acute and late reaction as well as the 5-year free survival for patients in Group 2 compare favorably with daily treatment. We conclude that 34.5 Gy given over 39 days is a safe and effective treatment for selected patients with bladder cancer.
PURPOSE: A dose-searching study was carried out treating selected elderly patients or patients with poor performance with bladder cancer with once weekly fractionation to determine an effective dose per fraction, and to evaluate acute and late effects resulting from this schedule. METHODS AND MATERIALS: Seventy patients with invasive transitional cell carcinoma of the bladder were entered in the study. The dose used was 36-39 Gy in six fractions over 35 days in 27 patients (Group 1). The remaining 43 patients were treated with 34.5 Gy in six fractions over 39 days (Group 2). RESULTS: Six patients developed Grade 1-2 European Organization for Research on Treatment of Cancer (EORTC) bowel reaction. Three patients in Group 1 developed Grade 3 late bowel reaction and a fourth patient developed Grade 4 reaction requiring colostomy. However, only one patient in Group 2 developed Grade 3 reaction. The difference between the two groups was statistically significant (chi 2 = 3.794, p = 0.05). CONCLUSIONS: The acute and late reaction as well as the 5-year free survival for patients in Group 2 compare favorably with daily treatment. We conclude that 34.5 Gy given over 39 days is a safe and effective treatment for selected patients with bladder cancer.
Authors: Piet Dirix; Sofie Vingerhoedt; Steven Joniau; Ben Van Cleynenbreugel; Karin Haustermans Journal: Support Care Cancer Date: 2015-05-16 Impact factor: 3.603
Authors: Benoîte Méry; Alexander T Falk; Avi Assouline; Jane-Chloé Trone; Jean-Baptiste Guy; Romain Rivoirard; Pierre Auberdiac; Julien Langrand Escure; Coralie Moncharmont; Guillaume Moriceau; Hweej Almokhles; Guy de Laroche; Cécile Pacaut; Aline Guillot; Cyrus Chargari; Nicolas Magné Journal: Int Urol Nephrol Date: 2015-05-17 Impact factor: 2.370
Authors: Shaista Hafeez; Fiona McDonald; Susan Lalondrelle; Helen McNair; Karole Warren-Oseni; Kelly Jones; Victoria Harris; Helen Taylor; Vincent Khoo; Karen Thomas; Vibeke Hansen; David Dearnaley; Alan Horwich; Robert Huddart Journal: Int J Radiat Oncol Biol Phys Date: 2017-02-09 Impact factor: 7.038
Authors: Shaista Hafeez; Emma Patel; Amanda Webster; Karole Warren-Oseni; Vibeke Hansen; Helen McNair; Elizabeth Miles; Rebecca Lewis; Emma Hall; Robert Huddart Journal: BMJ Open Date: 2020-05-26 Impact factor: 2.692